Efficacy of a joint didactic intervention using the Junta De Andalucía School for Patients method to control prothrombin time in patients taking anticoagulants: protocol for a randomized controlled trial

Leovigildo Ginel-Mendoza, Alfonso Hidalgo-Natera, Rocío Reina-Gonzalez, Rafael Poyato-Ramos, Juana Morales-Naranjo, Inmaculada Lupiañez-Pérez, Antonio Baca-Osorio, Miguel Gutiérrez-Jansen, María Paz Fernández-Lara, Diego Lozano-Noriega, Ulises Salgado-Carvallo, Cristina Bandera-García, Francisco Javier Navarro-Moya, Leovigildo Ginel-Mendoza, Alfonso Hidalgo-Natera, Rocío Reina-Gonzalez, Rafael Poyato-Ramos, Juana Morales-Naranjo, Inmaculada Lupiañez-Pérez, Antonio Baca-Osorio, Miguel Gutiérrez-Jansen, María Paz Fernández-Lara, Diego Lozano-Noriega, Ulises Salgado-Carvallo, Cristina Bandera-García, Francisco Javier Navarro-Moya

Abstract

Background: Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The ones in widespread use are vitamin K antagonists, whose plasma level is monitored by measuring prothrombin time using the international normalized ratio. If its values are out of the recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous research has shown that approximately 33% of patients keep having values at an inappropriate level. The purpose of the proposed study is to improve the international normalized ratio control results by a joint didactic intervention based on the Junta de Andalucía School for Patients method that will be implemented by anticoagulated patients themselves.

Methods: A randomized controlled trial will be undertaken at primary care centers from one healthcare area in Málaga (Andalusia, Spain).

Study population: patients participating in an oral anticoagulant therapy program of vitamin K antagonists. First step: identification of patients in the oral anticoagulation therapy program with international normalized ratio control of the therapeutic level at 65% or less over total time. Second step: patients with international normalized ratio (INR) control figures under 2 or above 3 will be assigned to two different groups: Group 1 or joint intervention group: patients will be instructed in the joint didactic "from peer to peer," by a previously trained and expert anticoagulant patient. Group 2 or control group: the control group will receive the usual clinical practice. They will be evaluated by nurses about once a month, except for cases in which their INR figures are under 2 or above 3, and those patients will be evaluated more frequently. A total of 312 individuals will be required (156 in each group) to detect differences in INR figures equal to or higher than 15% between the groups.

Study variables: time on therapeutic levels before and after the intervention; sociodemographic variables; vital signs; the existence of cardiovascular risk factors or accompanying diseases in the clinical records; laboratory test including complete blood counts, bleeding time, and prothrombin time or partial thromboplastin time; and blood chemistry, other prescribed drugs, and social support. A quasi-experimental analytic study with before-after statistical analysis of the intervention will be conducted. Linear regression models will be applied for the main variable results (international normalized ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases, and social support.

Trial registration: ClinicalTrials.gov NCT03647254 . Registered on 27 August 2018.

Keywords: Anticoagulants, acenocoumarol, warfarin, health education; Conditions: health education, patient education as topic, and blood coagulation; Patient participation; Randomized control trial.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
Timetable

References

    1. Odén A, Fablén M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006;117(5):493–499. doi: 10.1016/j.thromres.2004.11.025.
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007.
    1. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovas Qual Outcomes. 2008;1(2):84–91. doi: 10.1161/CIRCOUTCOMES.108.796185.
    1. Perk J, De Backer G, Gohlke H, Granam I, Reiner Z, Verschurren WMM, et al. European Guidelines on cardiovascular disease prevention in clinical practice: the Fifth Joint Task Forcé of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and invited experts) Int J Behav Med. 2012;19(4):403–488. doi: 10.1007/s12529-012-9242-5.
    1. Gómez-Doblas JJ, Muñiz J, Martin JJA, Rodriguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Espanola Cardiol Engl Ed. 2014;67:259–269. doi: 10.1016/j.recesp.2013.07.015.
    1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–1539. doi: 10.1016/j.amjcard.2009.07.022.
    1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584.
    1. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124.
    1. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J. 2010;31:2369–2429. doi: 10.1093/eurheartj/ehq278.
    1. Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014;348:g2116. doi: 10.1136/bmj.g2116.
    1. Riley RS, Rowe D, Fisher LM. Clinical utilization of the international normalized ratio (INR) J Clin Lab Anal. 2000;14(3):101–114. doi: 10.1002/(SICI)1098-2825(2000)14:3<101::AID-JCLA4>;2-A.
    1. Lobos-Bejarano JM, del Castillo-Rodríguez JC, Mena-González A, Alemán-Sánchez JJ, Cabrera de León A, Barón-Esquivias G, et al. Patients’ characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study. Med Clin (Barc) 2013;141:279–286. doi: 10.1016/j.medcli.2012.12.023.
    1. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–977. doi: 10.1160/TH11-05-0353.
    1. Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. J Electrocardiol. 2013;46(1):45–50. doi: 10.1016/j.jelectrocard.2012.08.011.
    1. Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2017; Available: .
    1. Barrios V, Escobar C, Prieto L, Osorio G, Polo J, Lobos JM, et al. Anticoagulation control in patients with nonvalgular atrial fibrillation attended at primary care centers in Spain. The PAULA study. Rev Espanola Cardiol Engl Ed. 2015;68:769–776. doi: 10.1016/j.recesp.2015.04.017.
    1. Cinza Sanjurio S, Rey Aldana D, Gestal Pereira E, Calvo Gómez C, ANFAGAL (Anticoagulación en pacientes con Fibrilación auricular en ámbito de atención primaria de Galicia) study Degree of anticoagulation control in patients with atrial fibrillation in Spain: need to minimize biases and contextualize results. Response by CInza Sanjurio et al. Rev Espanola Cardiol Engl Ed. 2016;69:357–358. doi: 10.1016/j.rec.2015.12.005.
    1. Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á, CALIFA study researchers Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Espanola Cardiol Engl Ed. 2015;68:761–768. doi: 10.1016/j.recesp.2014.11.022.
    1. Cárdenas Valladolid J, Mena Mateo J, Cañada Dorado MM, Rodriguez Morales D, Sánchez Perruca L. Implementation and improvement in a care program for the elderly on mulitiple medications in a primary care área. Rev Calid Asist. 2009;24(1):24–31. doi: 10.1016/S1134-282X(09)70072-7.
    1. Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013. 10.1002/14651858.CD008600.pub2.
    1. Nuño-Solinis R, Rodríguez-Pereira C, Piñera-Elorriaga K, Zaballa-González I, Bikandi-Irazabal J. Panorama of self-management initiatives in Spain. Gac Sanit. 2013;27:332–337. doi: 10.1016/j.gaceta.2013.01.008.
    1. Richards T, Montori VM, Godlee F, Lapsley P, Paul D. Let the patient revolution begin. BMJ. 2013;346:f2614. doi: 10.1136/bmj.f2614.

Source: PubMed

3
S'abonner